CN107007602A - 治疗阻塞性睡眠呼吸暂停的方法 - Google Patents

治疗阻塞性睡眠呼吸暂停的方法 Download PDF

Info

Publication number: CN107007602A
Authority: CN; China
Prior art keywords: sleep; main body; osa; pharmaceutical composition; patient
Prior art date: 2011-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201610821591.8A

Other languages

English (en)

Chinese (zh)

Inventor

樊建强

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC

Original Assignee

PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-28

Filing date

2012-01-27

Publication date

2017-08-04

2012-01-27 Application filed by PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC filed Critical PFANTASTIC MEDICAL RESEARCH INSTITUTE LLC

2017-08-04 Publication of CN107007602A publication Critical patent/CN107007602A/zh

Status Pending legal-status Critical Current

Links

208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 99
238000000034 method Methods 0.000 title claims abstract description 57
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims abstract description 76
229960002290 pyridostigmine Drugs 0.000 claims abstract description 76
230000007958 sleep Effects 0.000 claims abstract description 62
239000003814 drug Substances 0.000 claims abstract description 50
206010041235 Snoring Diseases 0.000 claims abstract description 38
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
238000011282 treatment Methods 0.000 claims abstract description 30
206010021079 Hypopnoea Diseases 0.000 claims description 37
239000008280 blood Substances 0.000 claims description 33
210000004369 blood Anatomy 0.000 claims description 33
208000008784 apnea Diseases 0.000 claims description 30
206010021143 Hypoxia Diseases 0.000 claims description 16
208000018875 hypoxemia Diseases 0.000 claims description 16
230000003860 sleep quality Effects 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 13
239000003937 drug carrier Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 7
238000010521 absorption reaction Methods 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 4
230000002496 gastric effect Effects 0.000 claims description 3
238000010790 dilution Methods 0.000 claims 1
239000012895 dilution Substances 0.000 claims 1
230000009467 reduction Effects 0.000 abstract description 18
208000024891 symptom Diseases 0.000 abstract description 15
230000002411 adverse Effects 0.000 abstract description 13
230000029058 respiratory gaseous exchange Effects 0.000 description 17
206010041349 Somnolence Diseases 0.000 description 16
239000003085 diluting agent Substances 0.000 description 11
230000031709 bromination Effects 0.000 description 10
238000005893 bromination reaction Methods 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
238000011160 research Methods 0.000 description 10
201000010099 disease Diseases 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000000902 placebo Substances 0.000 description 8
229940068196 placebo Drugs 0.000 description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
210000001367 artery Anatomy 0.000 description 6
206010019280 Heart failures Diseases 0.000 description 5
206010003119 arrhythmia Diseases 0.000 description 5
230000008859 change Effects 0.000 description 5
238000013270 controlled release Methods 0.000 description 5
230000000116 mitigating effect Effects 0.000 description 5
230000000241 respiratory effect Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
229960004373 acetylcholine Drugs 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
210000000981 epithelium Anatomy 0.000 description 4
230000035876 healing Effects 0.000 description 4
208000002815 pulmonary hypertension Diseases 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 3
206010022489 Insulin Resistance Diseases 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
230000019771 cognition Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
208000016097 disease of metabolism Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
208000030159 metabolic disease Diseases 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
210000001331 nose Anatomy 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
230000004622 sleep time Effects 0.000 description 3
208000037905 systemic hypertension Diseases 0.000 description 3
206010067484 Adverse reaction Diseases 0.000 description 2
206010003658 Atrial Fibrillation Diseases 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
206010008190 Cerebrovascular accident Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
238000007681 bariatric surgery Methods 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000007887 hard shell capsule Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000000414 obstructive effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
201000002859 sleep apnea Diseases 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000002618 waking effect Effects 0.000 description 2
208000036065 Airway Remodeling Diseases 0.000 description 1
241000208340 Araliaceae Species 0.000 description 1
206010006322 Breath holding Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102000003914 Cholinesterases Human genes 0.000 description 1
108090000322 Cholinesterases Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108010064719 Oxyhemoglobins Proteins 0.000 description 1
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
-1 acetylcholine ester Chemical class 0.000 description 1
230000002164 acetylcholinergic effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000024760 breath-holding Spells Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical class Br* 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940048961 cholinesterase Drugs 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229960003530 donepezil Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000008434 ginseng Nutrition 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
150000002926 oxygen Chemical class 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960002516 physostigmine salicylate Drugs 0.000 description 1
HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000005180 public health Effects 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000008667 sleep stage Effects 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
- A61F5/56—Devices for preventing snoring
- A61F5/566—Intra-oral devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Nursing (AREA)
Vascular Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN201610821591.8A 2011-01-28 2012-01-27 治疗阻塞性睡眠呼吸暂停的方法 Pending CN107007602A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161437272P	2011-01-28	2011-01-28
US61/437,272		2011-01-28
CN2012800065522A CN103458899A (zh)	2011-01-28	2012-01-27	治疗阻塞性睡眠呼吸暂停的方法

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2012800065522A Division CN103458899A (zh)	2011-01-28	2012-01-27	治疗阻塞性睡眠呼吸暂停的方法

Publications (1)

Publication Number	Publication Date
CN107007602A true CN107007602A (zh)	2017-08-04

Family

ID=46577943

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201610821591.8A Pending CN107007602A (zh)	2011-01-28	2012-01-27	治疗阻塞性睡眠呼吸暂停的方法
CN2012800065522A Pending CN103458899A (zh)	2011-01-28	2012-01-27	治疗阻塞性睡眠呼吸暂停的方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN2012800065522A Pending CN103458899A (zh)	2011-01-28	2012-01-27	治疗阻塞性睡眠呼吸暂停的方法

Country Status (6)

Country	Link
US (2)	US8753327B2 (2)
EP (1)	EP2672972B1 (2)
JP (2)	JP2014503593A (2)
CN (2)	CN107007602A (2)
CA (1)	CA2825309C (2)
WO (1)	WO2012103398A2 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107007602A (zh) *	2011-01-28	2017-08-04	辉达斯医学研究所	治疗阻塞性睡眠呼吸暂停的方法
ES2721976T3 (es) *	2014-03-03	2019-08-06	Sleep Innovations Pty Ltd	Dispositivo para el tratamiento de la apnea del sueño
US10166268B2 (en)	2014-07-25	2019-01-01	The George Washington University	Oxytocin improves treatment of obstructive sleep apnea
JP6480598B2 (ja)	2015-04-02	2019-03-13	ヒル−ロムサービシーズプライヴェートリミテッド	呼吸装置用マニホールド
JP7104044B2 (ja) *	2016-12-23	2022-07-20	コーニンクレッカフィリップスエヌヴェ	少なくとも２人のユーザ間でのいびきに対処するシステム
KR20240042261A (ko) *	2017-04-28	2024-04-01	더 브리검 앤드 우먼즈 하스피털, 인크.	수면 무호흡을 치료하기 위한 방법 및 조성물
HRP20241412T1 (hr)	2018-01-30	2024-12-20	Apnimed, Inc. (Delaware)	Postupci i pripravci namijenjeni liječenju apneje u snu ili običnog hrkanja
WO2019246145A1 (en) *	2018-06-18	2019-12-26	Kashiv Biosciences, Llc	Extended release compositions comprising pyridostigmine
CN112601568B (zh) *	2018-08-24	2024-07-26	皇家飞利浦有限公司	利用压力治疗系统提供睡眠治疗
BR112021015600A2 (pt)	2019-02-08	2021-10-05	The Brigham And Women's Hospital, Inc.	Métodos e composições para tratamento da apneia do sono
US11266837B2 (en)	2019-03-06	2022-03-08	Medtronic Xomed, Inc.	Position sensitive lingual muscle simulation system for obstructive sleep apnea
CN114504643B (zh) *	2021-12-24	2024-03-26	北京大学第一医院	抗IgE抗体在用于治疗OSAS中的应用
WO2024143302A1 (ja) *	2022-12-28	2024-07-04	西川株式会社	健康リスク判定システム、自律神経判定システム、生活改善システム、寝姿勢判定システム、寝姿勢判定プログラム、歯ぎしり検出システム、および歯ぎしり検出プログラム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6034117A (en) *	1995-12-19	2000-03-07	A & Science Invest Ab	Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2247662B (en)	1990-08-31	1994-11-02	Instance Ltd David J	Labels and manufacture thereof
US7297691B2 (en) *	2003-08-13	2007-11-20	Janssen Pharmaceutica N.V.	Treatment of sleep disorders with cholinesterase inhibitors
CA2622721A1 (en) *	2005-09-16	2007-03-22	Cereuscience Ab	Method and means of preventing and treating sleep disordered breathing
US20080066739A1 (en) *	2006-09-20	2008-03-20	Lemahieu Edward	Methods and systems of delivering medication via inhalation
US7984714B2 (en) *	2006-09-29	2011-07-26	Nellcor Puritan Bennett Llc	Managing obstructive sleep apnea and/or snoring using local time released agents
CN107007602A (zh) *	2011-01-28	2017-08-04	辉达斯医学研究所	治疗阻塞性睡眠呼吸暂停的方法

2012
- 2012-01-27 CN CN201610821591.8A patent/CN107007602A/zh active Pending
- 2012-01-27 CA CA2825309A patent/CA2825309C/en active Active
- 2012-01-27 JP JP2013551354A patent/JP2014503593A/ja active Pending
- 2012-01-27 CN CN2012800065522A patent/CN103458899A/zh active Pending
- 2012-01-27 US US13/359,692 patent/US8753327B2/en active Active
- 2012-01-27 EP EP12739245.4A patent/EP2672972B1/en active Active
- 2012-01-27 WO PCT/US2012/022825 patent/WO2012103398A2/en not_active Ceased
2014
- 2014-05-05 US US14/269,326 patent/US9295670B2/en active Active
2017
- 2017-01-04 JP JP2017000145A patent/JP6342525B2/ja active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6034117A (en) *	1995-12-19	2000-03-07	A & Science Invest Ab	Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
许庚: "《耳鼻咽喉科疾病临床诊断与治疗方案》", 31 August 2010, 科学技术文献出版社 *

Also Published As

Publication number	Publication date
JP2014503593A (ja)	2014-02-13
EP2672972A4 (en)	2014-09-10
US20120197235A1 (en)	2012-08-02
CA2825309C (en)	2019-10-01
WO2012103398A2 (en)	2012-08-02
CN103458899A (zh)	2013-12-18
US8753327B2 (en)	2014-06-17
EP2672972A2 (en)	2013-12-18
US20140238412A1 (en)	2014-08-28
CA2825309A1 (en)	2012-08-02
WO2012103398A9 (en)	2012-09-27
JP2017095485A (ja)	2017-06-01
JP6342525B2 (ja)	2018-06-13
US9295670B2 (en)	2016-03-29
EP2672972B1 (en)	2020-11-04

Legal Events

Date	Code	Title	Description
2017-08-04	PB01	Publication
2017-08-04	PB01	Publication
2017-08-29	SE01	Entry into force of request for substantive examination
2017-08-29	SE01	Entry into force of request for substantive examination
2018-06-15	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1241728 Country of ref document: HK
2023-03-24	RJ01	Rejection of invention patent application after publication
2023-03-24	RJ01	Rejection of invention patent application after publication	Application publication date: 20170804
2024-08-23	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1241728 Country of ref document: HK

Publication	Publication Date	Title
CA2825309C (en)	2019-10-01	Pyridostigmine for the treatment of obstructive sleep apnea
Tingting et al.	2018	Non-surgical treatment of obstructive sleep apnea syndrome
Dicpinigaitis	2007	Experimentally induced cough
Zaremba et al.	2016	Continuous positive airway pressure mitigates opioid-induced worsening of sleep-disordered breathing early after bariatric surgery
PT705099E (pt)	2002-03-28	Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central
Guilleminault et al.	2009	Obstructive sleep apnea syndrome
Simmons	2012	Neurology of sleep and sleep-related breathing disorders and their relationships to sleep bruxism
Vretzakis et al.	2005	Influence of an external pacemaker on bispectral index
Batra et al.	2005	Ketamine pretreatment with venous occlusion attenuates pain on injection with propofol
HK1241728A1 (en)	2018-06-15	Methods for treating obstructive sleep apnea
Dalsasso et al.	2005	Low-dose ketamine with clonidine and midazolam for adult day care surgery
Gogoi	2022	Dr. Juganta Jyoti Gogoi, Dr. Anshul Singla, Dr. Amrita Puri, Dr. Rakshita Kathia and Dr. Atika Tulsyan
Robertson	1967	Intravenous anaesthesia and analgesia
Kun et al.	2000	A pilot experience of the use of intramuscular ketamine for paediatric sedation in an Accident and Emergency department
Song et al.	2025	Comparative Study of Dexmedetomidine Administration Routes in Pediatric Patients Receiving Endoscopic Low-temperature Plasma Adenotonsillar Ablation
Culebras	2007	Sleep disorders and neuromuscular disorders
Balkan et al.	2005	The laryngeal mask airway (LMA™) in paediatric ophthalmic anaesthesia practice
KR20250000641A (ko)	2025-01-03	수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법
Dobbin et al.	2002	Obstructive sleep apnea: recognition and management considerations for the aged patient
Casati et al.	2005	A clinical comparison between bispectral index (BIS) and high frequency EEG signal detection (SNAP)
Tutiven	2012	Anaesthesia for paediatric ophthalmic surgery
Jiang et al.	2019	Risk factors for bradycardia and desaturation in infants undergoing ophthalmological surgeries: a retrospective cohort study
Davidson et al.	1993	Neuromuscular blockade: Nursing interventions and case studies from infancy to adulthood
Turcios	1996	Beta2-Adrenergic Agents in Asthma
Sleep	2013	Sleep Stages